knowledge -WSS

knowledge

author：knowledge 2025-09-30 01:03:16 - browse：85251

Amylyx founders — Justin Klee (left) and Joshua Cohen are the co-founders and co-CEOs of Amylyx Pharmaceuticals. Kayana Szymczak for STAT

Amylyx Pharmaceuticals said Friday that its treatment for ALS, called Relyvrio, failed to provide any benefit for patients in a large clinical trial — a stunning outcome that now has the company considering a voluntary withdrawal of the approved medicine from the market.

“This is really hard for us, and it’s really hard for our team who care so much, but it’s so much harder for people with ALS and their families, and we have to keep that perspective,” said a somber Justin Klee, Amylyx’s co-founder and co-CEO, in an interview with STAT on Thursday evening.

In the Phase 3 study involving 664 people with ALS, Relyvrio failed to outperform a placebo on an ALS functional rating scale that measures the ability to perform daily living tasks, walk, breathe, speak, and swallow. The company did not provide detailed results for the study’s primary goal, but said the calculation for statistical significance was 0.67 — well above the 0.05 threshold for success and an indication that Relyvrio provided no benefit at all.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： Care demand spikes challenge UnitedHealth’s provider arm

WSS

It shouldn't be easy to buy synthetic DNA to recreate a deadly virus

Care demand spikes challenge UnitedHealth’s provider arm

Manchin, Huntsman team up to talk platform for 'unity' ticket that could run in 2024

Making AI in medicine accessible to smaller, and rural hospitals

4 killed in mass shooting in Georgia, shooter remains on the loose: Police

Brain worms: The science behind RFK Jr.'s parasitic infection

Wikipedia

knowledge

focus

Continuity nursing helped my family in our darkest PICU moments

CDC wastewater surveillance dashboard to track bird flu hotspots

BioMarin wins approval for gene therapy to treat hemophilia A

Readout LOUD podcast: brain research, obesity drug sales, Novartis

Walensky prepares to leave CDC — and Congress — behind

RFK Jr. accused of antisemitic claims about COVID but insists he was misunderstood

Bright Health sells Medicare Advantage business to Molina

Study: People of West African ancestry at greater risk of cardiac amyloidosis

At least 13 dead in Texas as scorching temps continue

Study: People of West African ancestry at greater risk of cardiac amyloidosis

focus

It shouldn't be easy to buy synthetic DNA to recreate a deadly virus

Why police arrested suspected Gilgo Beach killer away from his house

Telehealth startups turn to complex chronic diseases

Researchers on aging grapple with how to calculate biological age

Medicare says breakthrough device reimbursement rule to come by summer

Everything to know for the next Powerball drawing as jackpot hits $1 billion

entertainment

explore

leisure time

entertainment